To generate drug signatures in human WM35 melanoma cell line. WM35 cell line was plated at 4 x 105 cells/mL overnight and treated with trifluridine or lactimidomycin at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest. Overall design: To find out whether drug signatures generated in human melanoma cell lines are predictive of outcome in melanoma patients, we generated trifluorothymidine(TFT) and lactimidomycin(LTM) signatures in cell lines WM35 . The expression of drug signatures were then tested by using GSSA (Gene Signature Survival Analysis) method to find out correlation with clinical outcome of melanoma patients.